Genesis R&D Extends Use of MorphoSys' HuCAL Antibodies for Autoimmune Rx Development

Oct 08, 2007

NEW YORK (GenomeWeb News) — MorphoSys today said Genesis Research and Development will continue using HuCAL-based antibodies in its drug-development research.

New Zealand-based Genesis will use the antibodies, developed by MorphoSys’ AbD Serotec segment, against the target molecule FGFR5 for validations and pre-clinical studies for its Zyrogen drug, which is being studied for certain autoimmune diseases, according to Genesis’ website.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

DNA Tests Considered to Verify Relatedness at Border

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

First of 'Right to Try'

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

This Week in Nature

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

How Old Were They?

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

Main menu